Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Forecast & Target Price

View the latest analyst price targets and forecasts to stay informed on market expectations. Click here to open.

MESO

Mesoblast Ltd ADR

Nov 27 • 04:00PM ET

11.58

Dollar change +0.53
Percentage change 4.80	%

Healthcare • Biotechnology • Australia • NASD

Peers: BMRN SRPT IONS SGMO BLUE ALNY FATE CARA CYTK KPTI

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.89	Insider Own	-	Shs Outstand	114.12M	Perf Week	12.10%
Market Cap	1.32B	Forward P/E	-	EPS next Y	-0.51	Insider Trans	-	Shs Float	-	Perf Month	27.81%
Income	-87.71M	PEG	-	EPS next Q	-	Inst Own	1.36%	Short Float	-	Perf Quarter	78.98%
Sales	5.89M	P/S	224.36	EPS this Y	22.78%	Inst Trans	409.47%	Short Ratio	9.01	Perf Half Y	53.38%
Book/sh	4.21	P/B	2.75	EPS next Y	25.58%	ROA	-	Short Interest	1.68M	Perf Year	335.34%
Cash/sh	0.55	P/C	20.99	EPS next 5Y	48.80%	ROE	-	52W Range	1.61 - 12.18	Perf YTD	426.36%
Dividend Est.	-	P/FCF	-	EPS past 5Y	12.34%	ROI	-15.05%	52W High	-4.92%	Beta	3.53
Dividend TTM	-	Quick Ratio	1.18	Sales past 5Y	2.11%	Gross Margin	-166.13%	52W Low	619.25%	ATR (14)	0.71
Dividend Ex-Date	-	Current Ratio	1.18	EPS Y/Y TTM	16.39%	Oper. Margin	-996.33%	RSI (14)	64.58	Volatility	4.50% 6.42%
Employees	73	Debt/Eq	0.25	Sales Y/Y TTM	-	Profit Margin	-1488.95%	Recom	1.00	Target Price	12.15
Option/Short	Yes / Yes	LT Debt/Eq	0.21	EPS Q/Q	10.96%	Payout	-	Rel Volume	0.62	Prev Close	11.05
Sales Surprise	-38.79%	EPS Surprise	-47.51%	Sales Q/Q	-3.91%	Earnings	Aug 28 AMC	Avg Volume	186.70K	Price	11.58
SMA20	16.38%	SMA50	24.92%	SMA200	72.22%	Trades		Volume	116,552	Change	4.80%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-24-24	Upgrade	Maxim Group	Hold → Buy	$12
Aug-29-24	Upgrade	Jefferies	Hold → Buy
Jul-23-24	Upgrade	Piper Sandler	Neutral → Overweight	$4 → $11
Aug-31-23	Upgrade	Jefferies	Hold → Buy
Aug-07-23	Downgrade	Maxim Group	Buy → Hold
Aug-04-23	Downgrade	William Blair	Outperform → Mkt Perform
Aug-04-23	Downgrade	Piper Sandler	Overweight → Neutral	$7 → $2
Mar-09-23	Initiated	William Blair	Outperform	$8
Dec-06-22	Downgrade	Jefferies	Buy → Hold
Sep-06-22	Initiated	Piper Sandler	Overweight	$7
Apr-07-21	Upgrade	Maxim Group	Hold → Buy	$18
Dec-22-20	Downgrade	Maxim Group	Buy → Hold
Dec-04-20	Downgrade	Chardan Capital Markets	Neutral → Sell	$7.50
Oct-22-20	Initiated	RBC Capital Mkts	Sector Perform	$12
Aug-14-20	Reiterated	Maxim Group	Buy	$16 → $22
May-28-20	Reiterated	H.C. Wainwright	Buy	$14 → $21
Jan-31-19	Resumed	H.C. Wainwright	Buy	$6.50
Mar-22-18	Downgrade	Credit Suisse	Neutral → Underperform
Feb-28-18	Reiterated	Cantor Fitzgerald	Buy	$20 → $23
Aug-31-17	Initiated	Oppenheimer	Outperform	$16

Show Previous Ratings

Nov-14-24 06:37AM	Mesoblast Issues 2 Million Warrants for Strategic Flexibility (TipRanks)
Oct-30-24 07:11PM	Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024 (GlobeNewswire)
Oct-19-24 06:30AM	Mesoblast Advances Cellular Medicines Amid FDA Hopes (TipRanks)
Sep-29-24 08:55PM	Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch (GlobeNewswire)
Aug-31-24 05:14PM	10 Best Australian Stocks To Buy According to Hedge Funds (Insider Monkey)
07:27PM	Loading…
Aug-28-24 07:27PM	Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024 (GlobeNewswire)
Aug-27-24 07:25PM	Mesoblast Financial Results and Corporate Update Webcast (GlobeNewswire)
Jul-30-24 09:13PM	Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024 (GlobeNewswire)
Jul-23-24 07:53AM	FDA Accepts Mesoblast's Biologics License Application (BLA) for Ryoncil in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) (GlobeNewswire) +9.54%
Jul-21-24 08:45PM	Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain (GlobeNewswire)
Jul-08-24 08:37PM	Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) (GlobeNewswire)
Jul-02-24 08:04AM	Mesoblast (MESO) Soars 208% YTD on Positive Regulatory Updates (Zacks)
Jul-01-24 07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
01:55AM	Mesoblast to File Biologics License Application for Ryoncil FDA Approval Next Week (GlobeNewswire)
Jun-02-24 08:23PM	Mesoblast Corporate Presentation at Investor Conference (GlobeNewswire)
09:05PM	Loading…
Apr-29-24 09:05PM	Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024 (GlobeNewswire) +13.78% -7.04%
Mar-30-24 11:49AM	10 Best Long Term ASX Stocks To Invest In (Insider Monkey)
Mar-27-24 11:00AM	Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up (Zacks) -11.20%
Mar-25-24 10:34PM	United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD) (GlobeNewswire) +78.64%
Mar-24-24 07:55AM	11 Best ASX Stocks To Buy Now (Insider Monkey)
Mar-13-24 07:30PM	Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer (GlobeNewswire) -8.27%
Mar-10-24 07:54PM	United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD) (GlobeNewswire)
Mar-03-24 08:25AM	Mesoblast Limited (NASDAQ:MESO) Q2 2024 Earnings Call Transcript (Insider Monkey)
Feb-28-24 05:57PM	Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023 (GlobeNewswire) -5.74%
Feb-26-24 07:00AM	Mesoblast Financial Results and Corporate Update Webcast (GlobeNewswire)
Feb-14-24 07:46PM	United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor (Rexlemestrocel-L) in Children With Congenital Heart Disease (GlobeNewswire) +5.96%
Jan-30-24 09:13PM	Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023 (GlobeNewswire)
Jan-19-24 11:30AM	Mesoblast (MESO) Up on Rare Pediatric Disease Tag for Heart Drug (Zacks) +11.63%
Jan-18-24 06:36PM	United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor (Rexlemestrocel-L) in Children With Congenital Heart Disease (GlobeNewswire)
Nov-27-23 07:28AM	Mesoblast files applications with US FDA for HLHS therapy (Pharmaceutical Business Review)
06:56PM	Loading…
Nov-26-23 06:56PM	Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease (GlobeNewswire)
Nov-21-23 06:32PM	Mesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHD (GlobeNewswire) +10.74%
Oct-30-23 08:04PM	Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2023 (GlobeNewswire) +5.98%
Sep-26-23 06:18AM	Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee (GlobeNewswire)
Sep-22-23 04:59PM	Health Care Roundup: Market Talk (The Wall Street Journal)
Sep-21-23 03:30AM	Key Outcomes From FDA Type A Meeting and Mesoblast Next Steps to Achieve RYONCIL Approval (GlobeNewswire)
Aug-30-23 07:07PM	Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2023 (GlobeNewswire) +12.59%
Aug-29-23 07:00AM	Mesoblast Financial Results and Corporate Update Webcast (GlobeNewswire)
Aug-04-23 09:38AM	Apple downgraded, Amazon upgraded: Wall Street's top analyst calls (The Fly) -58.90%
Aug-03-23 08:10PM	Mesoblast Receives Complete Response From U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children (GlobeNewswire)
Jul-30-23 08:31PM	Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2023 (GlobeNewswire)
Jun-04-23 08:21PM	Mesoblast Director Philip R. Krause, M.D., Appointed to Strategic Advisory Role (GlobeNewswire)
May-25-23 07:28PM	Mesoblast Reports Operational and Financial Highlights for Quarter Ended March 31, 2023 (GlobeNewswire) +5.22%
May-24-23 07:00AM	Mesoblast Financial Results and Corporate Update Webcast (GlobeNewswire)
Apr-27-23 09:00PM	Appendix 4C Quarterly Activity Report (GlobeNewswire)
Apr-25-23 08:47PM	Mesoblast Completes Private Placement (GlobeNewswire)
Mar-21-23 09:20PM	FDA Schedules Pre-License Inspection of Remestemcel-L Manufacturing (GlobeNewswire)
Mar-07-23 07:03PM	FDA Accepts Mesoblasts Resubmission of the Biologic License Application for Remestemcel-L In Children with Steroid-Refractory Acute Graft Versus Host Disease as a Complete Response and Sets Goal Date of August 2, 2023 (GlobeNewswire) -5.90% +23.76%
Feb-27-23 05:13PM	Mesoblast Reports Operational and Financial Highlights for Quarter Ended December 31, 2022 (GlobeNewswire)
04:49PM	DREAM-HF Phase 3 Trial Results for Mesoblast Cell Therapy in Heart Failure Published in Journal of the American College of Cardiology (JACC) (GlobeNewswire)
Feb-26-23 07:38PM	Mesoblast Financial Results and Corporate Update Webcast (GlobeNewswire)
Feb-16-23 06:16PM	Remestemcel-L Clinical and Potency Studies Presented at Premier Meeting of Transplantation Research and Therapy (GlobeNewswire) -7.82%
Feb-08-23 06:09PM	FDA Grants Regenerative Medicine Advanced Therapy (Rmat) Designation for Rexlemestrocel-L in Chronic Low Back Pain (GlobeNewswire)
Jan-31-23 06:30PM	Mesoblast Resubmits Biologic License Application (BLA) to FDA for Remestemcel-L in Children With Steroid-Refractory Acute Graft Versus Host Disease (Sr-aGVHD) (GlobeNewswire) +8.79%
04:40AM	Appendix 4C Quarterly Activity Report (GlobeNewswire)
Dec-22-22 07:18PM	Mesoblast and Oaktree Extend Availability Period of Undrawn Tranches of Financing Facility (GlobeNewswire)
Dec-15-22 12:00PM	Mesoblast Limited (MESO) Upgraded to Buy: Here's What You Should Know (Zacks) -5.15%
Dec-02-22 03:13PM	Mesoblast Limited's (ASX:MSB) Shift From Loss To Profit (Simply Wall St.)
Nov-23-22 09:38AM	Mesoblast Lead Product Shows Durable Long-Term Survival At Four Years In Kids With Graft Versus Host Disease (Benzinga)
Nov-22-22 06:32PM	Children Treated With Remestemcel-L Show Long-Term Survival Through Four Years in Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD) (GlobeNewswire)
06:01PM	Mesoblast Reports Financial Results and Operational Highlights for the Period Ended September 30, 2022 (GlobeNewswire)
Nov-21-22 06:00AM	Mesoblast Financial Results and Corporate Update Webcast (GlobeNewswire) +5.50%
Oct-30-22 07:50PM	Mesoblast Operational and Financial Highlights for Quarter Ended September 30, 2022 (GlobeNewswire)
Oct-02-22 07:52PM	Mesoblast Submits New Information to FDA IND File in Response to Items in the CRL to the Remestemcel-L BLA for SR-aGVHD (GlobeNewswire)
Aug-30-22 07:05PM	Mesoblast Reports Financial Results and Operational Highlights for Fiscal Year Ended June 30, 2022 (GlobeNewswire) +8.42%
Aug-29-22 08:14PM	Mesoblast Corporate Update and Financial Results Webcast (GlobeNewswire)
Aug-18-22 07:00AM	Jane Bell Joins Mesoblast Board (GlobeNewswire)
Jul-29-22 07:05AM	Appendix 4C Quarterly Activity Report (GlobeNewswire)
Jul-11-22 08:40PM	Rexlemestrocel-L to be Highlighted at Maxims Panel on Late-Stage Advancements in Heart Failure Therapeutics and Management (GlobeNewswire) -5.12%
Jun-28-22 11:54PM	The past five years for Mesoblast (ASX:MSB) investors has not been profitable (Simply Wall St.)
Jun-23-22 12:05PM	INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES FORMING THE SHARE CAPITAL (GlobeNewswire)
Jun-20-22 12:06PM	AVAILABILITY OF THE 2021-2022 UNIVERSAL REGISTRATION DOCUMENT INCLUDING THE COMPOSITION OF THE BOARD OF DIRECTORS, APPOINTMENTS AND REAPPOINTMENTS OF DIRECTORS PROPOSED AT THE SHAREHOLDERS' GENERAL MEETING OF JULY 26, 2022 (GlobeNewswire)
Jun-09-22 07:00AM	Mesoblast Key Opinion Leader Event Series for Investors & Analysts (GlobeNewswire)
May-31-22 08:15PM	Operational Highlights and Financial Results for the Period Ended March 31, 2022 (GlobeNewswire)
May-08-22 08:15PM	Perenti Global (ASX:PRN) shareholders have endured a 44% loss from investing in the stock three years ago (Simply Wall St.)
May-05-22 08:40PM	What Type Of Shareholders Make Up Mesoblast Limited's (ASX:MSB) Share Registry? (Simply Wall St.)
Apr-28-22 08:35PM	Appendix 4C Quarterly Activity Report (GlobeNewswire)
Apr-13-22 10:25AM	BioCardia (BCDA) Gains FDA Nod for ARDS Cell Therapy Study (Zacks)
Mar-28-22 09:30PM	Mesoblast Limited (MESO) Q1 2022 Earnings Call Transcript (Motley Fool)
Mar-23-22 08:40PM	Philip R. Krause, M.D., Former FDA Deputy Chief for Vaccines, Joins Mesoblast Board (GlobeNewswire) -6.92% +6.47%
Feb-27-22 05:18PM	Is Mesoblast (ASX:MSB) Using Debt In A Risky Way? (Simply Wall St.)
Feb-24-22 05:30PM	Operational Highlights and Financial Results for the Period Ended December 31, 2021 (GlobeNewswire)
05:57AM	Mesoblast Corporate Update and Financial Results Webcast (GlobeNewswire)
Feb-20-22 06:19PM	Rapid Improvement and Remission in Patients With Refractory Ulcerative Colitis and Crohns Colitis After Direct Injection of Remestemcel-L by Colonoscopy (GlobeNewswire)
Feb-01-22 07:20PM	Mesoblast Appoints Dr. Eric Rose as Chief Medical Officer (GlobeNewswire)
Jan-30-22 07:16PM	Appendix 4C Quarterly Activity Report (GlobeNewswire)
Jan-24-22 06:45PM	Mesoblast to Participate in Edison Groups Global Healthcare Open House Virtual Conference From January 25-27th, 2022 (GlobeNewswire)
Jan-11-22 08:26PM	Single Dose of Mesoblasts Allogeneic Cell Therapy Provides Durable Pain Reduction for at Least Three Years in Patients With Degenerative Disc Disease (GlobeNewswire)
Dec-30-21 06:38PM	Mesoblast Provides Update Following Meeting With FDAs OTAT on Remestemcel-L for Children With Acute Graft Versus Host Disease (GlobeNewswire)
Dec-15-21 07:09PM	FDAs OTAT in Agreement With 12-Month Reduction in Pain as Primary Endpoint for Chronic Low Back Pain Program (GlobeNewswire) +19.18%
10:00AM	Down 35.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Mesoblast Limited (MESO) (Zacks)
Dec-13-21 07:18PM	Update on Novartis Agreement (GlobeNewswire) -6.49% -27.60%
Dec-05-21 06:47PM	Rexlemestrocel-L Shows Greatest Treatment Benefit on Major Adverse Cardiovascular Events in High-Risk Heart Failure Patients With Diabetes and/or Myocardial Ischemia (GlobeNewswire)
Dec-02-21 04:57PM	Shareholders in Mesoblast (ASX:MSB) are in the red if they invested a year ago (Simply Wall St.) -5.20%
Dec-01-21 10:00AM	Mesoblast Limited (MESO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Nov-29-21 10:00AM	Wall Street Analysts Believe Mesoblast Limited (MESO) Could Rally 157%: Here's is How to Trade (Zacks)
Nov-23-21 06:09PM	Operational Highlights and Financial Results for the Period Ended September 30, 2021 (GlobeNewswire)
07:18AM	Mesoblast Corporate Update and Financial Results Webcast (GlobeNewswire)
Nov-22-21 06:51AM	Mesoblast Announces Debt Refinancing And Expansion With Oaktree Capital (Benzinga)
Nov-21-21 07:31PM	Mesoblast and Oaktree Capital Enter Into Refinancing and Expansion of Senior Debt Facility (GlobeNewswire)

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MESO

Mesoblast Ltd ADR

Upgrade your FINVIZ experience